Anticancer slow release agent of nimustine and its progression agent

A slow-release agent and synergist technology, applied in the field of anti-cancer sustained-release agents, can solve problems such as unclear effects, achieve the effects of convenient drug injection, reduce toxicity, and increase drug concentration

Inactive Publication Date: 2007-02-28
JINAN KANGQUAN PHARMA TECH
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the effect of ACNU on other tumors is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0127] Put 90mg of polylactic acid (PLA) with a molecular weight of 20000-40000 as pharmaceutical excipients into the container, add 100ml of organic solvent to dissolve it in dichloromethane, add 10mg of Nimustine, shake again and vacuum dry to remove the organic solvent . Shake well and vacuum dry to remove organic solvents. The dried drug-containing solid composition was freeze-pulverized into a micropowder containing 10% by weight nimustine, and then suspended in physiological saline containing 1.5% sodium carboxymethyl cellulose to prepare the corresponding suspension Type sustained-release injection, viscosity is 360cp-480cp (at 25℃-30℃). The subcutaneous release time is 25-30 days.

Embodiment 2

[0129] Put 75mg of polylactic acid (PLA) with a molecular weight of 30000-50000 as pharmaceutical excipients into the container, add 100ml of organic solvent to dissolve it in dichloromethane, add 25mg of Nimustine, shake again and vacuum dry to remove the organic solvent . The dried solid composition is immediately shaped, and after packaging, it is ray sterilized to obtain an anti-cancer in vivo implant containing 25% by weight of nimustine for curing solid tumors. The subcutaneous release time is 35-40 days.

Embodiment 3

[0131] Put 95mg of polylactic acid (PLA) with a molecular weight of 25000-40000 as pharmaceutical excipients into the container, add 100ml of organic solvent to dissolve in dichloromethane, add 5mg of Nimustine, shake again and vacuum dry to remove the organic solvent . The dried solid composition is immediately shaped, and then ray sterilized after being dispensed to obtain an anti-cancer in vivo implant containing 5% by weight nimustine for curing solid tumors. The subcutaneous release time is 30-40 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
glass transition temperatureaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

Disclosed is a slow release injection for treating solid tumors which comprises slow release auxiliary materials and active anticancer constituents, wherein the active anticancer constituents include Nimustine or the combination of Nimustine and its synergists (such as Paclitaxe, camptothecine or cytophosphanel). The viscosity of the slow release injection is 10-650cp (at 20-30 deg C), and the active anticancer constituents can also be made into slow release implanting agent. The slow release subsidiary materials mainly comprise bio-compactable and degradable macromolecular polymers, when locally dispensed on the tumor, the composition not only can lower down the whole body toxicity reaction of the anti-cancer medicament, but also can selectively increase the tumor local medicinal concentration, the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can also be improved. The solid tumors include glioma, osteosarcoma, lymphoma, lung carcinoma, intestinal cancer, and breast cancer.

Description

(1) Technical field [0001] The invention relates to an anticancer slow-release agent carrying nimustine and its synergist, and belongs to the technical field of medicines. Mainly sustained-release injections and sustained-release implants. (2) Background technology [0002] Although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. In my country, about 1.6 million people suffer from cancer each year, and nearly 1.3 million people die from cancer, accounting for one-fifth of the total deaths. The incidence of cancer is increasing year by year and is showing a trend of younger age. According to data, in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics of the World Health Organization, the global cancer incidence will increase by 50% by 2020, and the number of cases will increase to 15 million. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K31/505A61K31/337A61K31/4745A61K31/675A61K47/34A61P35/00A61K47/26
Inventor 孔庆忠刘玉燕邹会凤张红军张婕
Owner JINAN KANGQUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap